n-酰基腙和2,5-取代1,3,4-恶二唑衍生物作为无毒抗菌剂的生物学评价和计算模型研究。

IF 2.8 4区 医学 Q2 PHARMACOLOGY & PHARMACY Current pharmaceutical design Pub Date : 2025-01-01 DOI:10.2174/0113816128361524250131110036
Betul Giray, Nil Kaya, Martina Fiabane, Ayse Seyma Buyuk, Hatice Başpinar Kucuk, Semra Sardas, Mattia Mori
{"title":"n-酰基腙和2,5-取代1,3,4-恶二唑衍生物作为无毒抗菌剂的生物学评价和计算模型研究。","authors":"Betul Giray, Nil Kaya, Martina Fiabane, Ayse Seyma Buyuk, Hatice Başpinar Kucuk, Semra Sardas, Mattia Mori","doi":"10.2174/0113816128361524250131110036","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The increasing use of antibiotics coupled with the lack of innovative and effective antimicrobial agents has increased the development of antimicrobial resistance (AMR) worldwide. To overcome the AMR-associated prolonged disease duration and increased mortality rates, new antimicrobial agents are in high demand. In this context, hydrazone and oxadiazole derivatives are endowed with remarkable biocidal activity, becoming profitable scaffolds in the design of antimicrobial candidates.</p><p><strong>Methods: </strong>In this study, the antimicrobial effects of N-acyl hydrazones 1-15 and 2,5-disubstituted 1,3,4- oxadiazoles 16-27 against <i>Escherichia coli</i> ATCC 25922, <i>Staphylococcus aureus</i> ATCC 29213, <i>Bacillus subtilis</i> ATCC 6633, and clinically isolated <i>Shigella sonnei, Klebsiella pneumoniae</i>, and <i>Candida albicans</i> were evaluated. For this purpose, Kirby-Bauer disc diffusion and MIC tests were carried out, indicating that most of these compounds were active against tested microorganisms. Particularly, several compounds proved active against E. coli, whereas S. aureus showed higher resistance. The genotoxic potential of most active compounds was determined by <i>in vitro</i> alkaline comet assay, and they were found to be non-toxic at studied concentrations.</p><p><strong>Results: </strong>Finally, molecular docking and dynamics (MD) studies identified four compounds as potential inhibitors of bacterial DNA gyrase B (GyrB).</p><p><strong>Conclusion: </strong>Further exploration of molecular determinants revealed favourable drug-like properties, highlighting the potential of these molecules for subsequent hit-to-lead optimization studies.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":"2611-2624"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biological Evaluation and Computational Modelling Studies on <i>N</i>-acyl Hydrazone and 2,5-Disubstituted 1,3,4-Oxadiazole Derivatives as Non-toxic Antimicrobial Agents.\",\"authors\":\"Betul Giray, Nil Kaya, Martina Fiabane, Ayse Seyma Buyuk, Hatice Başpinar Kucuk, Semra Sardas, Mattia Mori\",\"doi\":\"10.2174/0113816128361524250131110036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The increasing use of antibiotics coupled with the lack of innovative and effective antimicrobial agents has increased the development of antimicrobial resistance (AMR) worldwide. To overcome the AMR-associated prolonged disease duration and increased mortality rates, new antimicrobial agents are in high demand. In this context, hydrazone and oxadiazole derivatives are endowed with remarkable biocidal activity, becoming profitable scaffolds in the design of antimicrobial candidates.</p><p><strong>Methods: </strong>In this study, the antimicrobial effects of N-acyl hydrazones 1-15 and 2,5-disubstituted 1,3,4- oxadiazoles 16-27 against <i>Escherichia coli</i> ATCC 25922, <i>Staphylococcus aureus</i> ATCC 29213, <i>Bacillus subtilis</i> ATCC 6633, and clinically isolated <i>Shigella sonnei, Klebsiella pneumoniae</i>, and <i>Candida albicans</i> were evaluated. For this purpose, Kirby-Bauer disc diffusion and MIC tests were carried out, indicating that most of these compounds were active against tested microorganisms. Particularly, several compounds proved active against E. coli, whereas S. aureus showed higher resistance. The genotoxic potential of most active compounds was determined by <i>in vitro</i> alkaline comet assay, and they were found to be non-toxic at studied concentrations.</p><p><strong>Results: </strong>Finally, molecular docking and dynamics (MD) studies identified four compounds as potential inhibitors of bacterial DNA gyrase B (GyrB).</p><p><strong>Conclusion: </strong>Further exploration of molecular determinants revealed favourable drug-like properties, highlighting the potential of these molecules for subsequent hit-to-lead optimization studies.</p>\",\"PeriodicalId\":10845,\"journal\":{\"name\":\"Current pharmaceutical design\",\"volume\":\" \",\"pages\":\"2611-2624\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pharmaceutical design\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113816128361524250131110036\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128361524250131110036","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

导言:抗生素使用的增加,加上缺乏创新和有效的抗微生物药物,增加了世界范围内抗微生物药物耐药性(AMR)的发展。为了克服与抗菌素耐药性相关的疾病持续时间延长和死亡率增加,对新型抗菌素的需求很大。在这种情况下,腙和恶二唑衍生物被赋予了显著的生物杀灭活性,成为设计候选抗菌药物的有利支架。方法:研究n -酰基腙1-15和2,5-取代1,3,4-恶二唑16-27对大肠杆菌ATCC 25922、金黄色葡萄球菌ATCC 29213、枯草芽孢杆菌ATCC 6633以及临床分离的索内志贺氏菌、肺炎克雷伯菌和白色念珠菌的抑菌效果。为此,进行了Kirby-Bauer圆盘扩散和MIC试验,表明大多数这些化合物对被测微生物有活性。特别是,一些化合物被证明对大肠杆菌有活性,而金黄色葡萄球菌表现出更高的耐药性。大多数活性化合物的基因毒性潜力是通过体外碱性彗星试验确定的,在研究浓度下发现它们是无毒的。结果:最后,分子对接和动力学(MD)研究确定了四种化合物作为细菌DNA回转酶B (GyrB)的潜在抑制剂。结论:对分子决定因素的进一步探索揭示了有利的药物样性质,突出了这些分子在随后的hit-to-lead优化研究中的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Biological Evaluation and Computational Modelling Studies on N-acyl Hydrazone and 2,5-Disubstituted 1,3,4-Oxadiazole Derivatives as Non-toxic Antimicrobial Agents.

Introduction: The increasing use of antibiotics coupled with the lack of innovative and effective antimicrobial agents has increased the development of antimicrobial resistance (AMR) worldwide. To overcome the AMR-associated prolonged disease duration and increased mortality rates, new antimicrobial agents are in high demand. In this context, hydrazone and oxadiazole derivatives are endowed with remarkable biocidal activity, becoming profitable scaffolds in the design of antimicrobial candidates.

Methods: In this study, the antimicrobial effects of N-acyl hydrazones 1-15 and 2,5-disubstituted 1,3,4- oxadiazoles 16-27 against Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213, Bacillus subtilis ATCC 6633, and clinically isolated Shigella sonnei, Klebsiella pneumoniae, and Candida albicans were evaluated. For this purpose, Kirby-Bauer disc diffusion and MIC tests were carried out, indicating that most of these compounds were active against tested microorganisms. Particularly, several compounds proved active against E. coli, whereas S. aureus showed higher resistance. The genotoxic potential of most active compounds was determined by in vitro alkaline comet assay, and they were found to be non-toxic at studied concentrations.

Results: Finally, molecular docking and dynamics (MD) studies identified four compounds as potential inhibitors of bacterial DNA gyrase B (GyrB).

Conclusion: Further exploration of molecular determinants revealed favourable drug-like properties, highlighting the potential of these molecules for subsequent hit-to-lead optimization studies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
期刊最新文献
The Emerging Roles of lncRNA GAPLINC as a Promising Biomarker and Therapeutic Target in Oncology. Reciprocal Mechanisms Linking Cancer and Cardiovascular Disease: Emerging Paradigms in Onco-Cardiology. Bromocriptine Attenuated Ulcerative Colitis and Colonic Inflammation by Inhibiting IL-1β, Likely through NF-κB Down-regulation: Integrated Network Pharmacology and in vivo Experimental Validation. Network Pharmacology, Molecular Docking, and Experimental Validation Reveal the Mechanism of Qingfudaotan Formula in PCOS Treatment. A Critical Review of the Biological Significance and Synthesis Challenges of Phytonutrients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1